La catena delle opzioni mostra i dati chiave delle opzioni azionarie di SHF Hldgs a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per SHF Hldgs..

SHF Hldgs (NASDAQ:SHFS) Azioni, Catena delle Opzioni

SHF Hldgs

SHF Holdings Inc is a financial services provider to cannabis-related businesses. It offers reliable access to banking solutions for cannabis, hemp, CBD, and ancillary operators, making communities safer, driving growth in local economies, and fostering long-term partnerships. The group, through its financial institution clients, implements accountability, transparency, monitoring, reporting, and risk mitigation measures while meeting Bank Secrecy Act obligations in line with FinCEN guidance on cannabis-related businesses. Its services include Program Management Support, Customer Generation, Ongoing Program Auditing, and Compliance Monitoring, among others.

&nbsp;On July 17, 2025, Telomir Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TELO#NASDAQ">TELO</a>) reported new preclinical results evaluating the effects of its lead candidate, Telomir-1, &nbsp;in a murine xenograft model using PC3 human prostate cancer cells. The data demonstrated that Telomir-1 reversed epigenetic silencing by DNA methylation of the STAT1 gene, a tumor suppressor and immune response regulator, in a dose-dependent manner. &nbsp;

News

TELO

Telomir Pharmaceuticals Announced Earlier, Data Show Telomir-1 Reverses Epigenetic Gene Silencing of STAT1, Restoring Tumor Suppressor in Human Prostate Cancer Cells, Outperforming Chemotherapy and Rapamycin

After totaling his car, a Reddit user jumped back into the <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/07/46324594/used%E2%80%91car-boom-prices-supercharging-carvana-autonation-stocks">used car market</a> hoping to find a decent replacement. What he found instead was sticker shock.
<h2 class="wp-block-heading">Prices For High-Mileage Cars Are Up. Way Up.</h2>
In a <a href="https://www.reddit.com/r/UsedCars/comments/1ly1eni/this_market_is_ridiculous/">post</a> titled &#8220;This Market Is Ridiculous,&#8221; the buyer recalled buying a 2006 Cadillac CTS with 64,000 miles back in 2012 for just $6,000. Now, more than a decade later, he's seeing base-model 2016 Honda Civics with 80,000 miles listed for $15,000, barely less than their original manufacturer's suggested retail price.
&#8220;So you&#8217;re telling me that car only lost $3,000 to $4,000 over 10 years and 100K miles? Get out of here!&#8221; he wrote. &#8220;There are no more starter cars that are safe, reliable, with less than 100K [miles] that are affordable anymore.&#8221;
Don't Miss:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/money/mode-mobile-accredited-investor-offer">Accredited investors can claim pre-IPO shares of Mode Mobile for just $0.30</a>—with up to 120% bonus shares—before this Uber-style disruption hits the public markets</li>
<li>Named a TIME Best Invention and Backed by 5,000+ Users, Kara's Air-to-Water Pod Cuts Plastic and Costs — <a href="https://www.benzinga.com/money/americans-spend-1000-per-year-on-plastic-water-bottles-kara-pod-gives-you-clean-drinking-water-by-pulling-moisture-from-the-air">And You Can Invest At Just $6.37/Share</a></li>
</ul>
He's not alone in that sentiment. Hundreds of commenters chimed in, sharing their own frustrations about a market where decade-old cars with over 150,000 miles are still commanding $10,000 or more.
One user said they saw a &#8220;stock good condition late &#8217;90s Toyota just shy over 300k miles for $18k.&#8221; Another added, &#8220;Every time I save enough for an all-cash purchase, the prices go up and the quality of used cars in my price range goes down.&#8221;
<h2 class="wp-block-heading">COVID, Inflation And A Crushed Supply</h2>
Many in the thread blamed the inflated prices on the long-term effects of COVID-19. Factory shutdowns and chip shortages slashed new car production, which reduced future used car supply. Several commenters also pointed to the lingering impact of the 2009 &#8220;Cash for Clunkers&#8221; program, which removed hundreds of thousands of older vehicles from circulation.
&#8220;Covid was arguably worse because there was no replenishment supply due to supply chain issues,&#8221; one person explained. &#8220;Now the market for cars from the last decade are all 100K+ miles and largely still 5 figures.&#8221;
Trending: $100k+ in investable assets? <a href="https://www.benzinga.com/money/wiseradvisor-retirement-planning">Match with a fiduciary advisor for free to learn how you can maximize your retirement and save on taxes</a> – no cost, no obligation.
Others mentioned inflation and the devaluation of the dollar as culprits. &#8220;The price of vehicles hasn&#8217;t gone up, the value of the dollar has gone down,&#8221; one commenter argued. Another quipped, &#8220;$5,000 is the new $10,000.&#8221;
On top of that, President Donald Trump&#8216;s 25% auto tariffs are now <a href="https://www.benzinga.com/markets/tech/25/07/46314078/used-car-prices-see-biggest-surge-since-2022-as-trump-tariffs-shake-auto-market-report">shaking the market</a> even more. The Manheim Index, a key measure of used vehicle prices, surged 1.6% in June from May and is up 6.3% year-over-year—the sharpest rise since 2022, according to <a href="https://site.manheim.com/en/services/consulting/used-vehicle-value-index.html">Cox Automotive</a>.
&#8220;Tariffs really impacted new sales and supply, which impacted the used marketplace as well,&#8221; said Jeremy Robb, Cox Automotive's senior director of economic and industry insights. With fewer off-lease vehicles returning to the market, prices are staying elevated.
<h2 class="wp-block-heading">When Used Costs Nearly As Much As New</h2>
Several buyers reported skipping the used market entirely. &#8220;I said I&#8217;d &#8216;never&#8217; buy new,&#8221; one person wrote. &#8220;Maybe $7k less than new with 30-40K miles on it was all I could find a few years ago. Guess who bought new???&#8221;
See Also: This AI-Powered Trading Platform Has 5,000+ Users, 27 Pending Patents, and a $43.97M Valuation — <a href="https://www.benzinga.com/money/finally-a-fully-automated-trading-platform-for-individual-investors?">You Can Become an Investor for Just $500.25</a>
Financing was also a factor. As <a href="https://www.benzinga.com/personal-finance/25/01/43074274/dave-ramsey-warns-asking-how-much-a-month-could-cost-you-10000-extra-on-your-car-purchase">interest rates on used car loans</a> hit double digits, many found that new vehicles offered better terms and warranties for a slightly higher sticker price. One buyer said they leased a new car for $20 more per month than a used one with 30,000 miles.
<h2 class="wp-block-heading">Deals Are Rare And Private Sales Are Competitive</h2>
A few commenters shared success stories, but they were often the result of aggressive searching, luck, or knowing the right people. One person scored a 2012 car for $800. Another found a 2006 Corolla in a small town 60 miles outside their metro area from a single-owner seller with full maintenance records.
Others gave up entirely. One parent said they paid $12,000 for a car with a $7,000-$8,000 value, only to have the engine blow within a year. The mechanic advised them to part it out. &#8220;It HURTS,&#8221; they wrote.
The original poster summed it up: &#8220;Honestly, can't justify spending my hard-earned money on purchasing a used car right now.&#8221;
Read Next: Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"> Here&#8217;s how you can earn passive income with just $10.</a>
Image: Shutterstock

Personal Finance

A Used Car Buyer Is Baffled By Prices, Says There Are No More Affordable Safe And Reliable Starter Cars With Less Than 100K Miles

<a href="https://www.bloomberg.com/news/articles/2025-07-17/meta-hires-two-key-apple-ai-experts-after-poaching-their-boss?taid=68798bf3f71ade000190df83&amp;utm_campaign=trueanthem&amp;utm_content=business&amp;utm_medium=social&amp;utm_source=twitter&amp;sref=XIUS5d6L&amp;embedded-checkout=true" title="https://www.bloomberg.com/news/articles/2025-07-17/meta-hires-two-key-apple-ai-experts-after-poaching-their-boss?taid=68798bf3f71ade000190df83&amp;utm_campaign=trueanthem&amp;utm_content=business&amp;utm_medium=social&amp;utm_source=twitter&amp;sref=XIUS5d6L&amp;embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-07-17/meta-hires-two-key-apple-ai-experts-after-poaching-their-boss?taid=68798bf3f71ade000190df83&amp;utm_campaign=trueanthem&amp;utm_content=business&amp;utm_medium=social&amp;utm_source=twitter&amp;sref=XIUS5d6L&amp;embedded-checkout=true</a>

Tech

AAPL

Bloomberg Reported Meta Hires Mark Lee, Tom Gunter, Two Key Apple AI Experts After Poaching Their Boss

MLGO

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

CREG

Insulet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) has outperformed the market over the past 10 years by 12.88% on an annualized basis producing an average annual return of 24.39%. Currently, Insulet has a market capitalization of $19.95 billion. 
Buying $1000 In PODD: If an investor had bought $1000 of PODD stock 10 years ago, it would be worth $8,969.94 today based on a price of $283.45 for PODD at the time of writing.
<h3>Insulet's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752795912_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

PODD

$1000 Invested In Insulet 10 Years Ago Would Be Worth This Much Today

Orla Mining (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ORLA#AMEX">ORLA</a>) has outperformed the market over the past 5 years by 13.55% on an annualized basis producing an average annual return of 27.63%. Currently, Orla Mining has a market capitalization of $3.72 billion. 
Buying $1000 In ORLA: If an investor had bought $1000 of ORLA stock 5 years ago, it would be worth $3,677.28 today based on a price of $11.45 for ORLA at the time of writing.
<h3>Orla Mining's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752795012_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ORLA

$1000 Invested In Orla Mining 5 Years Ago Would Be Worth This Much Today

The <a href="https://www.benzinga.com/news/politics/25/06/46091456/trump-made-europepay-in-a-big-way-nato-chief-lauds-role-in-boosting-defense-spending">NATO</a> Innovation Fund<a href="https://www.globenewswire.com/news-release/2025/06/30/3107673/0/en/Portal-Biotech-Raises-35-Million-Series-A-Leveraging-AI-to-Deliver-the-World-s-First-Full-Length-Single-Molecule-Protein-Sequencer.html"> has co-led</a> a $35 million Series A round into Portal Biotech, a U.K.-based life sciences startup that claims it has developed the world's first platform for full-length, single-molecule protein sequencing.
This marks the fund's first investment in a biotechnology firm and signals a strategic move to boost <a href="https://www.benzinga.com/25/04/45032800/global-defense-budgets-surge-to-27-trillion-as-europe-and-middle-east-lead-steepest-increase-since-cold-war-report">global defense</a> against future biological threats,<a href="https://www.reuters.com/sustainability/climate-energy/nato-fund-backs-biotech-startup-push-counter-biological-threats-2025-06-30/"> Reuters</a> says. Portal Biotech was founded in 2021 by Andy Heron and Giovanni Maglia, according to the company's <a href="https://www.portalbiotech.com/">website</a>. The following year, after the Russian invasion of Ukraine, the NATO Innovation Fund was launched with plans to invest more than $1 billion into cutting-edge defense technologies, Reuters reports. The fund is backed by 24 NATO member nations, including the U.S., U.K., Germany, Italy, and France, according to the NATO Innovation Fund&#8217;s <a href="https://www.nif.fund/about/">website</a>.
Don't Miss:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/money/mode-mobile-accredited-investor-offer">Accredited investors can claim pre-IPO shares of Mode Mobile for just $0.30</a>—with up to 120% bonus shares—before this Uber-style disruption hits the public markets</li>
<li>$100k+ in investable assets? <a href="https://www.benzinga.com/money/wiseradvisor-retirement-planning">Match with a fiduciary advisor for free to learn how you can maximize your retirement and save on taxes</a> – no cost, no obligation.</li>
</ul>
According to Portal Biotech, its technology allows rapid, on-site protein sequencing without the need for large labs or long turnaround times, offering a real-time advantage in identifying both known and engineered pathogens.
According to Ana Bernardo-Gancedo, senior associate at the NATO Innovation Fund, the technology could play a defining role in future biosecurity efforts across Allied nations. "Portal Biotech's ability to characterise proteins at the molecular level onsite anywhere could help detect engineered biological threats faster and more accurately — crucial in defending against biowarfare and preparing us for the next pandemic, boosting the resilience of Allied nations for generations to come," Bernardo-Gancedo said in the statement.
<h2 class="wp-block-heading">Why This Breakthrough Could Be the Key to Precision Medicine and Pandemic Prevention</h2>
Portal Biotech's breakthrough positions it as a leading innovator in the race to unlock what many in the life sciences field have called the "holy grail" of proteomics: full-length, single-molecule protein sequencing.
Trending: Named a TIME Best Invention and Backed by 5,000+ Users, Kara's Air-to-Water Pod Cuts Plastic and Costs — <a href="https://www.benzinga.com/money/americans-spend-1000-per-year-on-plastic-water-bottles-kara-pod-gives-you-clean-drinking-water-by-pulling-moisture-from-the-air">And You Can Invest At Just $6.37/Share</a>
According to the company, the ability to read intact proteins at this level of detail, without breaking them into fragments, has never been achieved before and holds the potential to reshape drug discovery, diagnostics, and biological research. Portal Biotech says its technology addresses long-standing blind spots in how proteins are analyzed, offering a new level of accuracy, speed, and accessibility for labs worldwide.
Legacy methods like mass spectrometry slice proteins into fragments, often losing critical information about protein modifications and functions, Portal Biotech says. The startup's benchtop instruments aim to provide full-length sequencing at the single-molecule level, maintaining the integrity of the protein data while significantly cutting costs and time.
Portal Biotech CEO Andy Heron said in the statement that the startup's AI-enhanced sequencing tools will allow researchers to monitor the proteome with unmatched accuracy and speed. &#8220;These powerful advances are essential for accelerating drug discovery and enhancing diagnostic precision, positioning Portal Biotech as the frontrunner in the race to unlock the full potential of protein sequencing,&#8221; he added.&nbsp;&nbsp;
The company expects its platform to not only accelerate go-or-no-go decisions in drug pipelines but also to enable portable, field-level surveillance tools for pandemic and biowarfare preparedness.
See Also: This AI-Powered Trading Platform Has 5,000+ Users, 27 Pending Patents, and a $43.97M Valuation — <a href="https://www.benzinga.com/money/finally-a-fully-automated-trading-platform-for-individual-investors?">You Can Become an Investor for Just $500.25</a>
<h2 class="wp-block-heading">NATO, Earlybird, and Big-Name VCs Line Up to Back Portal Biotech's Bold Play</h2>
Portal Biotech says the $35 million round was co-led by the NATO Innovation Fund and Earlybird Venture Capital, with support from returning investors SCVC, Pillar VC, 8VC, Amino Collective, and Outsized. New investors include We Venture Capital, British Business Bank, and WS Investment Company, the venture arm of Wilson Sonsini.
The founding team includes scientists with deep expertise in nanopore genomics, drawing from over a decade of research in the Maglia lab. Dr. Rabab Nasrallah, principal at Earlybird Health Fund, said in the statement that Portal Biotech is poised to do for proteomics what next-generation DNA sequencing did for genomics.
The raise will support the expansion of Portal's commercial efforts, research and development team, and pharmaceutical partnerships. With the human genome already sequenced, Portal Biotech aims to decode the proteome next, potentially unlocking answers that DNA alone could never reveal.
Read Next: Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"> Here&#8217;s how you can earn passive income with just $10.</a>
Image: Shutterstock

NATO Just Funded A British Startup That Says Its AI Tech Can Spot Deadly Bio Threats Before They Spread—Even The Ones We Didn't Know Existed

Brown &amp; Brown (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRO#NYSE">BRO</a>) has outperformed the market over the past 5 years by 4.56% on an annualized basis producing an average annual return of 18.65%. Currently, Brown &amp; Brown has a market capitalization of $34.34 billion. 
Buying $1000 In BRO: If an investor had bought $1000 of BRO stock 5 years ago, it would be worth $2,379.57 today based on a price of $104.13 for BRO at the time of writing.
<h3>Brown &amp; Brown's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752793216_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Brown & Brown 5 Years Ago Would Be Worth This Much Today

A new voter poll shows that people want third-party options as President Donald Trump's approval rating continues to be below 50%. While Elon Musk could be <a href="https://www.benzinga.com/news/politics/25/07/46265725/elon-musk-announces-formation-of-america-party-emerges-in-wake-of-donald-trumps-historic-spending-bill">launching a third party,</a> voters are saying no thanks to one from the world's richest man.
What Happened: Shareholders of Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) may love hearing that voters might not be interested in a <a href="https://www.benzinga.com/news/politics/25/07/46210411/musk-third-party-odds-hit-47-can-the-tesla-chief-do-what-no-one-has-since-1853">third party launch </a>by CEO Musk.
After all, the promised launch of the America Party by Musk could see the CEO spend more time in politics and less time leading the electric vehicle giant.
A Quinnipiac <a href="https://poll.qu.edu/poll-release?releaseid=3928">poll </a>finds that voters aren't impressed with Musk's option.
Quinnipiac recently asked voters if they would consider joining a third party as an alternative to the Republican and Democratic parties.
A near majority (49%) said yes they would consider, while 45% said they would not consider. The remainder said they didn't know. Men and women were equally divided in the poll with 49% of men saying yes and 45% saying no and the same result reported for women.
Broken down by political party, here were the results of considering joining a third party:
<ul class="wp-block-list">
<li>Republicans: 28% yes, 67% no</li>
<li>Democrats: 39% yes, 56% no</li>
<li>Independents: 75% yes, 21% no</li>
</ul>
While voters want a third party option, it appears they aren't happy with the option of one coming from Musk. When asked if they would consider joining a third party if created by Musk, the result significantly changed.
The results were 17% yes and 77% no, broken down as follows by political party and gender:
<ul class="wp-block-list">
<li>Republican: 18% yes, 74% no</li>
<li>Democrat: 6% yes, 90% no</li>
<li>Independent: 22% yes, 73% no</li>
<li>Men: 20% yes, 73% no</li>
<li>Women: 14% yes, 73% no</li>
</ul>
"There is a healthy appetite for a third party among American voters. But with Elon Musk leading the way, not so much," Quinnipiac University Polling Analyst Tim Malloy said.
Read Also: <a href="https://www.benzinga.com/news/politics/25/07/46294492/trump-warned-us-system-is-not-designed-for-third-parties-now-experts-doubt-elon-musks-america-party-will-even-be-ready-by-2026-midterms">Trump Warned US System Is &#8216;Not Designed&#8217; For Third Parties — Now Experts Doubt Elon Musk&#8217;s America Party Will Even Be Ready By 2026 Midterms</a>
Why It's Important: The Quinnipiac poll found that only 44% of voters approve of President Trump with 54% disapproving. This result was similar to a poll in late June from Quinnipiac.
One of the items that might be impacting the approval rating is the Jeffrey Epstein files. Sixty-three percent of voters in the poll said they disapprove of the Trump administration's handling of the files.
Trump also received approval ratings of under 50% across many issues, including the economy (42%), foreign policy (41%), trade (40%), and the Russia-Ukraine war (34%).
A third-party option could gain steam among voters for the first time in years based on the current results of polls and overall sentiment from voters. The problem is that this poll shows voters don't want Musk involved.
Prediction market <a href="https://polymarket.com/event/will-elon-register-the-america-party-by?tid=1752789090374">Polymarket </a>shows odds of 44% that Musk will register the America Party by the end of 2025.
Benzinga<a href="https://www.benzinga.com/news/politics/25/07/46341429/musks-politics-or-teslas-future-74-say-the-choice-is-clear"> recently asked readers </a>if this should be Musk&#8217;s focus going forward.
&#8220;Elon Musk is wading deeper into politics. Should he stay focused on Tesla and SpaceX — or keep speaking out?&#8221; Benzinga asked
The results were:
<ul class="wp-block-list">
<li>Stay focused on his companies: 74%</li>
<li>Do both – he can multitask: 21%</li>
<li>Keep speaking out: 5%</li>
</ul>
A large majority of readers polled said Musk should stay focused on his companies.&nbsp;Musk is the CEO of Tesla and&nbsp;SpaceX&nbsp;and is also involved with several other companies, including&nbsp;Neuralink&nbsp;and&nbsp;X. With the recent announcement that X CEO&nbsp;Linda Yaccarino&nbsp;<a href="https://www.benzinga.com/news/social-media/25/07/46329375/x-ceo-yaccarino-splits-with-elon-musk-after-two-years-says-best-is-yet-to-come-for-social-platform" target="_blank" rel="noreferrer noopener">is stepping down,</a>&nbsp;Musk's time commitment to the social media platform may increase.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/07/46332361/musk-political-push-to-hurt-tesla-stock-71-say-stock-will-fall-in-next-12-months">Musk Political Push To Hurt Tesla Stock: 71% Say Stock Will Fall In Next 12 Months</a></li>
</ul>
Photo: Shutterstock

Social Media

Politics

TSLA

Voters Want Third Party Option, But 77% Say 'Not So Much' To Elon Musk, While Trump Approval At 44%

It started with a stock short and ended with memes, jabs, and one of the messiest billionaire feuds in recent memory.
Bill Gates isn't new to criticism, but he didn't expect a full-on cold war with Elon Musk. At least, not over Tesla. "Once he heard I'd shorted the stock, <a href="https://www.benzinga.com/25/02/43880898/im-in-awe-bill-gates-says-elon-musk-is-brilliant-rich-and-influential-but-admits-hes-been-mean-to-me-at-times">he was super mean to me</a>," Gates told Walter Isaacson, the author of Musk's 2023 biography. Then came the part that made the quote instantly viral: "But he's super mean to so many people, so you can't take it too personally."
Gates confirmed he had bet against Tesla stock—shorting it—and according to Isaacson, that revelation didn't sit well with Musk. Text messages between the two billionaires, later confirmed by Musk himself, showed how quickly things soured. Musk asked Gates point-blank if he still held a "half billion dollar short position against Tesla." Gates admitted, "Sorry to say I haven't closed it yet. I would like to discuss philanthropy possibilities."
Don't Miss:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/money/mode-mobile-accredited-investor-offer">Accredited investors can claim pre-IPO shares of Mode Mobile for just $0.30</a>—with up to 120% bonus shares—before this Uber-style disruption hits the public markets</li>
<li>Named a TIME Best Invention and Backed by 5,000+ Users, Kara's Air-to-Water Pod Cuts Plastic and Costs — <a href="https://www.benzinga.com/money/americans-spend-1000-per-year-on-plastic-water-bottles-kara-pod-gives-you-clean-drinking-water-by-pulling-moisture-from-the-air">And You Can Invest At Just $6.37/Share</a></li>
</ul>
Musk didn't hold back. "Sorry, I cannot take your philanthropy on climate change seriously when you have a <a href="https://www.benzinga.com/personal-finance/management/25/07/46296787/elon-musk-says-bill-gates-bet-500-million-on-teslas-demise-then-had-the-nerve-to-ask-him-for-a-donation-boggles-the-mind">massive short position against Tesla</a>, the company doing the most to solve climate change," he replied. Days later, Musk posted a meme mocking Gates' weight and moved on—at least publicly.
But the drama didn't stop.
By 2025, their rift had ballooned into something far bigger than stock positions or bad memes. It's now a full-blown ideological clash, with Musk and Gates trading public blows over foreign aid, philanthropy, and how billionaires should use their wealth.
Trending: This AI-Powered Trading Platform Has 5,000+ Users, 27 Pending Patents, and a $43.97M Valuation — <a href="https://www.benzinga.com/money/finally-a-fully-automated-trading-platform-for-individual-investors?">You Can Become an Investor for Just $500.25</a>
In May, Gates accused Musk of harming the world's most vulnerable. After Musk and the Department of Government Efficiency cut funding to programs like the U.S. Agency for International Development, Gates told <a href="https://www.benzinga.com/25/05/45311187/the-picture-of-the-worlds-richest-man-killing-the-worlds-poorest-children-is-not-a-pretty-one-says-bill-gates-slamming-elon-musk-over-abrupt-usaid-cuts">reporters the decision "killed vulnerable children</a>." Musk shot back, calling the accusation false and referencing Gates' ties to disgraced financier and convicted sex offender Jeffrey Epstein, saying, "I wouldn't trust that guy to babysit my kids."
The feud escalated from there. Musk called USAID "beyond repair." Gates fired back, defending it as "the best of the world's development agencies." While Gates pledged to give away nearly his entire $200 billion fortune by 2045, Musk continued slashing what he saw as bloated government spending—touting a "move fast, cut waste" approach that echoes his tech playbook.
And despite their public platforms and billionaire status, there's been <a href="https://www.benzinga.com/personal-finance/25/03/44434228/elon-musk-said-bill-gates-would-be-obliterated-for-shorting-tesla-but-short-sellers-just-made-16-2-billion-in-3-months-betting-against-him">zero sign of reconciliation</a>. In fact, their feud now shapes how the public debates government responsibility, philanthropy, and who gets to define "doing good."
See Also: $100k+ in investable assets? <a href="https://www.benzinga.com/money/wiseradvisor-retirement-planning">Match with a fiduciary advisor for free to learn how you can maximize your retirement and save on taxes</a> – no cost, no obligation.
Gates leans toward strategic, long-term investment in public health and education. Musk prefers disruption, arguing that bureaucracy and inefficiency do more harm than good. One believes in continuity. The other believes in chaos—at least if it saves money and speeds things up.
For now, they remain on opposite sides of almost everything—from aid policy to social media etiquette. Gates apologized to Musk about the Tesla shorting. The relationship didn't recover. Instead, it evolved into a headline-grabbing standoff between two of the <a href="https://www.benzinga.com/personal-finance/24/11/41809171/bill-gates-says-being-a-billionaire-is-overrated-being-rich-brings-you-freedom-but-beyond-that-i">world's richest men</a>—and a reminder that even billionaires take things personally.
Read Next: Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"> Here&#8217;s how you can earn passive income with just $10.</a>
Images: Shutterstock

Bill Gates Says Elon Musk Was 'Super Mean' After He Shorted Tesla Stock — 'But He's Super Mean to So Many People'

Middleby (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIDD#NASDAQ">MIDD</a>) has outperformed the market over the past 20 years by 5.73% on an annualized basis producing an average annual return of 14.21%. Currently, Middleby has a market capitalization of $7.88 billion. 
Buying $1000 In MIDD: If an investor had bought $1000 of MIDD stock 20 years ago, it would be worth $14,215.76 today based on a price of $147.37 for MIDD at the time of writing.
<h3>Middleby's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752791413_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MIDD

$1000 Invested In Middleby 20 Years Ago Would Be Worth This Much Today

The Roundhill Video Games ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NERD#NASDAQ">NERD</a>) launched in 2019 and is having a great year in 2025 thanks to the launch of the <a href="https://www.benzinga.com/news/gaming/25/06/45776150/jensen-huang-says-nintendo-switch-2-has-ai-processors-to-enhance-gameplay-unlike-anything-weve-built-before">Switch 2 console</a> from Nintendo Co (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NTDOY#OTC">NTDOY</a>).
Roundhill Investments CEO Dave Mazza shares thoughts on the<a href="https://www.benzinga.com/news/gaming/25/07/46455645/250000-for-a-stapler-gamestop-turns-blunder-into-big-charity-win"> Switch 2 launch</a>, what sports games mean to Electronic Arts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>) and why GameStop Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) doesn't make the cut for inclusion in the ETF.
Switch 2 Success: The Nintendo Switch 2 launched with a price of $449, $150 above the cost of the original 2017 model. Despite the higher price, the console saw strong initial sales and continues to sell-out.
"All early datapoints say ‘blockbuster.' Nintendo sold 3.5 million Switch 2 units in the first four days, the fastest start for any console in the firm's history," Mazza told Benzinga.
Mazza said the strong early sales have Nintendo management guiding to ship 15 million consoles in the current fiscal year, which will lift revenue by more than 60% and operating profit by around 13%.
The Roundhill CEO said the consensus is that Nintendo could return to record earnings if the strong unit sales and strong software sales happen as quickly as the original Switch.
But it's not just the Switch 2 that makes a Nintendo investment exciting, Mazza told Benzinga. Nintendo is currently the largest holding at 12.1% of assets in the Roundhill Video Games ETF.
"The investment story increasingly pivots on monetizing intellectual property beyond plastic cartridges."
Mazza said this includes first-party software like the "Donkey Kong Bananza" game, mobile apps, royalties from movies and the company's theme-park footprint.
"Each new entertainment vertical widens reach, supports evergreen game sales and extends the duration of cash flows, which is an IP flywheel few peers can replicate."
Read Also: <a href="https://www.benzinga.com/news/gaming/25/06/45850712/microsoft-vs-nintendo-handheld-gaming-console-includes-nvidia-vs-amd-battle-which-one-will-come-out-on-top">Microsoft Vs. Nintendo Handheld Gaming Console Includes Nvidia Vs. AMD Battle: Which One Will Come Out On Top?</a>
Microsoft Vs. Nintendo?: A potential competitor to the Switch 2 could be coming with Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) announcing the ROG Xbox Ally and Ally 2. Mazza said these are more "portable Windows gaming PCs" than video game consoles.
"They aim at the enthusiast Steam-Deck tier rather than the family-friendly Switch demographic."
Mazza said success for the Microsoft handheld will come based on access to the full Xbox Game Pass library on day one, strong battery life and specs to run AAA titles and a price point of under $799.
"If Microsoft nails those three, the device can thrive alongside and not directly against Switch 2."
Mazza said Nintendo having NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) chips and Microsoft having Advanced Micro Devices Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) chips won't be a major selling point for gamers, but maybe to investors.
"The logo matter more to investors with Nvidia's presence signaling another growth beachhead, whereas gamers judge on real-world performance and ecosystem fit."
EA Sports: Electronic Arts releases sports titles annually and is growing its library thanks to the expansion in college sports.
"Sports titles are EA's cash cow as Madden and College Football together drove an upside revision to FY-25 bookings," Mazza told Benzinga.
Mazza said the report that a college basketball franchise could be returning to EA would mean another annualized franchise with "highly monetizable Ultimate-Team-style modes."
The Roundhill CEO estimates that a college basketball video game could sell four million titles conservatively and could mean $300 million in bookings for EA. The game could also increase engagement between gamers and EA in between football seasons.
GameStop Not In ETF: Investors might think that it makes sense to put video game retailer GameStop into the video game ETF, but that's not the case.
Mazza said there are several reasons GameStop doesn't make the ETF cut. The most important one is the ETF seeking to track the Nasdaq CTA Global Video Games Software Index, which GameStop isn't included.
The index includes publishers and developers of games and digital content creators, but doesn't include physical retailers.
Mazza also said GameStop's current financials would likely keep the stock out of the ETF.
"GameStop also fails the growth-quality screen: revenue is shrinking double-digits as sales migrate online, and recent meme-driven volatility has been disconnected from fundamentals."
NERD Price Action: The Roundhill Video Games ETF ended trading at $25.94 on Thursday versus a 52-week trading range of $14.50 to $26.75. The ETF is up 31.3% year-to-date in 2025 and up 57.7% over the last year. Nintendo, the largest holding in the ETF, is up 50.4% year-to-date in 2025.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/sports-betting/25/07/46481992/exclusive-sports-betting-etf-ceo-sizes-up-trumps-big-beautiful-bill-higher-taxes-espn-bet-success">EXCLUSIVE: Sports Betting ETF CEO Sizes Up Trump&#8217;s Big Beautiful Bill, Higher Taxes, ESPN Bet Success</a></li>
</ul>
Photo: agustin.photo via Shutterstock

Gaming

Specialty ETFs

Exclusives

Interview

ETFs

MSFT

NERD

NTDOY

NVDA

EXCLUSIVE: Video Game ETF CEO Says Switch 2 Is 'Blockbuster,' EA Gains From Sports, GameStop Doesn't Pass ETF Test

Expedia Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) has outperformed the market over the past 20 years by 2.18% on an annualized basis producing an average annual return of 10.66%. Currently, Expedia Group has a market capitalization of $23.28 billion. 
Buying $100 In EXPE: If an investor had bought $100 of EXPE stock 20 years ago, it would be worth $751.16 today based on a price of $182.50 for EXPE at the time of writing.
<h3>Expedia Group's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752790512_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EXPE

If You Invested $100 In This Stock 20 Years Ago, You Would Have This Much Today

General

Graco To Acquire Color Service For €63M; Expected To Close In Graco's Fiscal Q3 Following The Satisfaction Of Closing Conditions

Boeing And Gulf Air Today Announced An Agreement For The Purchase Of 12 787 Dreamliner Jets With Options For Six More As The Bahrain-Based Airline Looks To Further Develop Its International Network

Bicycle Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCYC#NASDAQ">BCYC</a>) underwent analysis by 7 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Bicycle Therapeutics and provided 12-month price targets. The average target is $22.0, accompanied by a high estimate of $32.00 and a low estimate of $14.00. Observing a downward trend, the current average is 20.61% lower than the prior average price target of $27.71. 
<img src="https://www.benzinga.com/files/images/story/2025/1752789683_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A clear picture of Bicycle Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$25.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Jeffrey Hung</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$17.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$32.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Kalpit Patel</td>
<td>B. Riley Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$14.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Reni Benjamin</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$22.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$29.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Peter Lawson</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$15.00</td>
<td>$40.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Bicycle Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Bicycle Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Bicycle Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Bicycle Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BCYC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Bicycle Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering Bicycle Therapeutics: A Closer Look</h2>
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.
<h3>Bicycle Therapeutics's Economic Impact: An Analysis</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Negative Revenue Trend: Examining Bicycle Therapeutics's financials over 3M reveals challenges. As of 31 March, 2025, the company experienced a decline of approximately -48.91% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Bicycle Therapeutics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -608.94%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Bicycle Therapeutics's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -7.92% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Bicycle Therapeutics's ROA stands out, surpassing industry averages. With an impressive ROA of -6.6%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Bicycle Therapeutics's debt-to-equity ratio is below the industry average. With a ratio of 0.01, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

BCYC

Demystifying Bicycle Therapeutics: Insights From 7 Analyst Reviews

In the last three months, 6 analysts have published ratings on IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>), offering a diverse range of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $543.83, a high estimate of $600.00, and a low estimate of $475.00. Marking an increase of 3.65%, the current average surpasses the previous average price target of $524.67. 
<img src="https://www.benzinga.com/files/images/story/2025/1752789665_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive IDEXX Laboratories. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daniel Clark</td>
<td>Leerink Partners</td>
<td>Raises</td>
<td>Outperform</td>
<td>$600.00</td>
<td>$580.00</td>
</tr>
<tr>
<td>Jonathan Block</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$540.00</td>
<td>$510.00</td>
</tr>
<tr>
<td>Daniel Clark</td>
<td>Leerink Partners</td>
<td>Raises</td>
<td>Outperform</td>
<td>$580.00</td>
<td>$515.00</td>
</tr>
<tr>
<td>Jonathan Block</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$510.00</td>
<td>$460.00</td>
</tr>
<tr>
<td>Erin Wright</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$558.00</td>
<td>$548.00</td>
</tr>
<tr>
<td>Michael Ryskin</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$475.00</td>
<td>$535.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to IDEXX Laboratories. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of IDEXX Laboratories compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for IDEXX Laboratories's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into IDEXX Laboratories's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/IDXX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on IDEXX Laboratories analyst ratings.</a>
<h2>Unveiling the Story Behind IDEXX Laboratories</h2>
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 35% of its revenue from outside the United States.
<h3>Breaking Down IDEXX Laboratories's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: IDEXX Laboratories displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 3.56%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: IDEXX Laboratories's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 24.31% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): IDEXX Laboratories's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 15.95% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): IDEXX Laboratories's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 7.46%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.73.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

IDXX

Expert Outlook: IDEXX Laboratories Through The Eyes Of 6 Analysts

Marqeta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MQ#NASDAQ">MQ</a>) underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Marqeta, revealing an average target of $5.5, a high estimate of $6.50, and a low estimate of $4.50. This current average has increased by 23.6% from the previous average price target of $4.45. 
<img src="https://www.benzinga.com/files/images/story/2025/1752789658_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of Marqeta among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bryan Keane</td>
<td>Deutsche Bank</td>
<td>Announces</td>
<td>Hold</td>
<td>$6.00</td>
<td>-</td>
</tr>
<tr>
<td>Sanjay Sakhrani</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$6.50</td>
<td>$4.50</td>
</tr>
<tr>
<td>Tien-Tsin Huang</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$6.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Ramsey El-Assal</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$5.00</td>
<td>$4.00</td>
</tr>
<tr>
<td>Timothy Chiodo</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$5.00</td>
<td>$4.75</td>
</tr>
<tr>
<td>Sanjay Sakhrani</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$4.50</td>
<td>$4.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Marqeta. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Marqeta compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Marqeta's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Marqeta's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MQ/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Marqeta analyst ratings.</a>
<h2>Get to Know Marqeta Better</h2>
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
<h3>Financial Milestones: Marqeta's Journey</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Marqeta's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 17.89%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Financials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Marqeta's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -5.94%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -0.8%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -0.59%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.01.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Marqeta's Future

In the last three months, 5 analysts have published ratings on Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>), offering a diverse range of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Evolent Health and provided 12-month price targets. The average target is $14.4, accompanied by a high estimate of $16.00 and a low estimate of $13.00. Observing a 4.35% increase, the current average has risen from the previous average price target of $13.80. 
<img src="https://www.benzinga.com/files/images/story/2025/1752789643_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The analysis of recent analyst actions sheds light on the perception of Evolent Health by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$16.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Constantine Davides</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$13.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Ryan MacDonald</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$15.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Constantine Davides</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$13.00</td>
<td>$13.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Evolent Health. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Evolent Health compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Evolent Health's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Evolent Health's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/EVH/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Evolent Health analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Evolent Health</h2>
Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The primary solutions provided by the company include specialty care management services, total cost of care management, and administrative services.
<h3>Evolent Health's Economic Impact: An Analysis</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Challenges: Evolent Health's revenue growth over 3M faced difficulties. As of 31 March, 2025, the company experienced a decline of approximately -24.39%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Evolent Health's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -14.94% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -7.46%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Evolent Health's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -2.78%, the company showcases efficient use of assets and strong financial health.
Debt Management: Evolent Health's debt-to-equity ratio is below the industry average at 0.93, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>What Are Analyst Ratings?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: Evolent Health In The Eyes Of 5 Experts

Financing

Press Releases

Safe Harbor Financial Successfully Modifies Debt Obligation with Partner Colorado Credit Union

Management

Newly Appointed Safe Harbor Financial CEO Terry Mendez Issues Letter to Shareholders

Safe Harbor Financial Names Mike Regan as Head of Investor Relations and Data Science

Earnings

Safe Harbor Financial Reports Fourth Quarter and Year-End 2024 Results

Safe Harbor Financial and Würk Partner to Expand Access to Cannabis Financial Services and Workforce Solutions

Safe Harbor Financial and FundCanna Announce Strategic Partnership to Expand Access to Capital for Cannabis Operators

Safe Harbor Financial Expands Executive Leadership Team with Appointments of Jeffrey Kay as SVP of Marketing and Dominic Marella as VP of Business Development

Safe Harbor Financial Partners with Bennett Thrasher to Deliver Advanced Financial Services to Cannabis Operators Nationwide

Safe Harbor Financial to Participate in the Benzinga Cannabis Capital Conference on June 8–10, 2025

Safe Harbor Financial CEO Terry Mendez to Serve as "Shark" during Conscious Capitalist Sessions at Psychedelic Science 2025

SHFS

Acacia Research Corporation - Common Stock

Acacia Research

Eason Technology Limited American Depositary Shares (each representing sixty-thousand (60,000) Ordinary Shares)

Comments

SHF Hldgs

SHF Hldgs (SHFS) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO